Authors who equally contributed to this work
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease
Article first published online: 29 SEP 2010
© 2010 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 124, Issue 2, pages 122–129, August 2011
How to Cite
Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Hüls, C., Zetterberg, H., Minthon, L., Wallin, Å. K., Andreasen, N., Talesa, V. N. and Blennow, K. (2011), Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease. Acta Neurologica Scandinavica, 124: 122–129. doi: 10.1111/j.1600-0404.2010.01435.x
- Issue published online: 7 JUL 2011
- Article first published online: 29 SEP 2010
- Accepted for publication August 12, 2010
- acetylcholinesterase inhibitors;
- total tau;
- phosphorylated tau;
- Alzheimer’s disease
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin ÅK, Andreasen N, Talesa VN, Blennow K. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease. Acta Neurol Scand: 2011: 124: 122–129. © 2010 John Wiley & Sons A/S.
Objectives – To measure cerebrospinal fluid (CSF) activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in patients with Alzheimer’s disease (AD) participating in randomized clinical trials from three European centers, before and after long-term treatment with different AChE inhibitors (AChEIs).
Materials and methods – Of the 144 patients included in the study, 104 were treated with donepezil, 15 with galantamine, 16 with rivastigmine, and nine with placebo. CSF AChE and BChE activities were measured at baseline and after 1- year treatment.
Results – Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Conversely, in rivastigmine group, a decrease in CSF activity of both enzymes was observed. CSF AChE and BChE activities were not correlated with the clinical outcome in any group considered. CSF biomarkers did not show any change after treatment.
Conclusions – AChEIs differently influence the activity of target enzymes in CSF independent of their pharmacodynamic effects.